当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Assessment of neutralization of Micrurus venoms with a blend of anti-Micrurus tener and anti-ScNtx antibodies.

Assessment of neutralization of Micrurus venoms with a blend of anti-Micrurus tener and anti-ScNtx antibodies.

Abstract：

BACKGROUND:Micrurus venoms contain two main groups of toxic protein components: short-chain α-neurotoxins (SNtx) and phospholipases type A2 (PLA2). In North America, generally, the Micrurus venoms have low abundance of SNtx compared to that of PLA2s; however, both are highly toxic to mammals, and consequently both can play a major role in the envenomation processes. Concerning the commercial horse-derived antivenoms against Micrurus from the North America region, they contain a relatively large amount of antibodies against PLA2s, and a low content of antibodies against short chain α-neurotoxins. This is mainly due to the lower relative abundance of SNtxs, and also to its poor immunogenicity due to their size and nature. Hence, Micrurus antivenoms made in North America usually present low neutralizing capacity towards Micrurus venoms whose lethality depend largely on short chain α-neurotoxins, such as South American Micrurus species. METHODS:Horses were hyperimmunized with either the venom of M. tener (PLA2-predominant) or a recombinant short-chain consensus α-neurotoxin (ScNtx). Then, the combination of the two monospecific horse antibodies (anti-M. tener and anti-ScNtx) was used to test their efficacy against eleven Micrurus venoms. RESULTS:The blend of anti-M. tener and anti-ScNtx antibodies had a better capacity to neutralize the lethality of diverse species from North, Central and South American Micrurus venoms. The antibodies combination neutralized both the ScNtx and ten out of eleven Micrurus venom tested, and particularly, it neutralized the venoms of M. distans and M. laticollaris that were neither neutralized by monospecific anti-M. tener nor anti-ScNtx. CONCLUSIONS:These results provide a proof-of-principle for using recombinant immunogens to enrich poor or even non-neutralizing antisera against elapid venoms containing short chain α-neurotoxins to develop antivenoms with higher effectiveness and broader neutralizing capacity.

journal_name

Vaccine

journal_title

Vaccine

authors

Archundia IG,de la Rosa G,Olvera F,Calderón A,Benard-Valle M,Alagón A,Corzo G

doi

10.1016/j.vaccine.2020.12.052

subject

Has Abstract

pub_date

2021-02-05 00:00:00

pages

1000-1006

issue

6

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(20)31632-7

journal_volume

39

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Characterization of virulence of Leptospira isolates in a hamster model.

    abstract：:Effort has been made to identify protective antigens in order to develop a recombinant vaccine against leptospirosis. Several attempts failed to conclusively demonstrate efficacy of vaccine candidates due to the lack of an appropriate model of lethal leptospirosis. The purposes of our study were: (i) to test the virul...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.04.085

    authors： Silva EF,Santos CS,Athanazio DA,Seyffert N,Seixas FK,Cerqueira GM,Fagundes MQ,Brod CS,Reis MG,Dellagostin OA,Ko AI

    更新日期：2008-07-23 00:00:00

  • Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections.

    abstract：BACKGROUND:Several chronic disease states have been identified as pneumococcal vaccination indications due to their ability to increase pneumococcal disease development and subsequent mortality. However, the risk of mortality according to the number of these disease states present is unknown. We sought to determine the...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.02.026

    authors： Morton JB,Morrill HJ,LaPlante KL,Caffrey AR

    更新日期：2017-03-23 00:00:00

  • The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.

    abstract：:To test the possibility of developing a combined vaccine against hepatitis A and E, groups of mice were immunized with different formulations containing different dosages of a commercially inactivated hepatitis A vaccine and a candidate recombinant hepatitis E vaccine. Monovalent vaccine components were used as contro...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.11.001

    authors： Dong C,Dai X,Meng JH

    更新日期：2007-02-19 00:00:00

  • Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector.

    abstract：:Enteroviruses elicit protective mucosal immune responses that could be harnessed as part of a strategy to prevent sexual transmission of the human immunodeficiency virus-1 (HIV-1). We report the construction of replication-competent recombinant vectors of coxsackievirus B3 (CVB3) that express one or more portions of t...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.04.035

    authors： Miller JP,Geng Y,Ng HL,Yang OO,Krogstad P

    更新日期：2009-06-19 00:00:00

  • Catching-up with pentavalent vaccine: Exploring reasons behind lower rotavirus vaccine coverage in El Salvador.

    abstract：:Rotavirus vaccine was introduced in El Salvador in 2006 and is recommended to be given concomitantly with DTP-HepB-Haemophilus influenzae type b (pentavalent) vaccine at ages 2 months (upper age limit 15 weeks) and 4 months (upper age limit 8 months) of age. However, rotavirus vaccination coverage continues to lag beh...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.07.092

    authors： Suarez-Castaneda E,Burnett E,Elas M,Baltrons R,Pezzoli L,Flannery B,Kleinbaum D,de Oliveira LH,Danovaro-Holliday MC

    更新日期：2015-11-27 00:00:00

  • Meningococcal surrogates of protection--serum bactericidal antibody activity.

    abstract：:Despite the availability of anti-microbial agents effective against Neisseria meningitidis, meningococcal disease continues to be a major global health problem, particularly in the very young. Serogroup A meningococci cause large epidemics in sub-Saharan Africa, whilst serogroups B and C organisms are responsible for ...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2005.01.051

    authors： Borrow R,Balmer P,Miller E

    更新日期：2005-03-18 00:00:00

  • Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain.

    abstract：:A nephropathogenic K2/01 strain of infectious bronchitis virus (IBV) was attenuated by 170 serial passages in embryonated chicken eggs for possible use as a future IBV vaccine strain. High-growth properties and narrow tissue tropisms (limited replication in respiratory tracts) were achieved by the adaptation process. ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.01.062

    authors： Lee HJ,Youn HN,Kwon JS,Lee YJ,Kim JH,Lee JB,Park SY,Choi IS,Song CS

    更新日期：2010-04-01 00:00:00

  • A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

    abstract：BACKGROUND:This phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults. METHODS:We enrolled 42 healthy, BCG-vaccinated adults into 4 groups: low dose Starter ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.10.102

    authors： Wilkie M,Satti I,Minhinnick A,Harris S,Riste M,Ramon RL,Sheehan S,Thomas ZM,Wright D,Stockdale L,Hamidi A,O'Shea MK,Dwivedi K,Behrens HM,Davenne T,Morton J,Vermaak S,Lawrie A,Moss P,McShane H

    更新日期：2020-01-22 00:00:00

  • The outer membrane protein, LamB (maltoporin), is a versatile vaccine candidate among the Vibrio species.

    abstract：:Maltoporin (LamB) is a family of outer membrane proteins. There has been no report of immunological characteristics of LamB in the Vibrio species so far. In this study, lamB genes from eight Vibrio strains were cloned and sequenced. The bioinformatics analysis indicated that sequence similarities of LamB proteins were...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.12.035

    authors： Lun J,Xia C,Yuan C,Zhang Y,Zhong M,Huang T,Hu Z

    更新日期：2014-02-07 00:00:00

  • The Children's Vaccine Initiative and vaccine supply: the role of the public sector.

    abstract：:'Children represent the most vulnerable segment of every society--and they are our present and future. Good health, especially of children, promotes personal and national development. Scientific progress, matched with improved capacities of all countries to immunize their children, provides an unparalleled opportunity...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(92)90323-c

    authors： van Noort RB

    更新日期：1992-01-01 00:00:00

  • Immunotherapy with combined DNA vaccines is an effective treatment for M. bovis infection in cattle.

    abstract：:Mycobacterium bovis causes tuberculosis in cattle. Because current therapies inadequately prevent disease spread, new therapies for M. bovis infections are urgently needed. We treated M. bovis-infected cattle with combinations of DNA vaccines, resulting in significantly reduced pulmonary bacterial loads compared with ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.12.055

    authors： Hu XD,Chen ST,Yu DH,Li SX,Cai H

    更新日期：2009-02-25 00:00:00

  • Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations.

    abstract：:Protein C deletion mutants of West Nile virus (WNV) were evaluated for their potential use as live virus vaccine candidates in vivo. Double and triple mutants carrying small deletions and second-site point mutations, as well as mutants with large deletions of 36 and 37 amino acid residues were tested in a stringent mo...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.06.045

    authors： Schlick P,Kofler RM,Schittl B,Taucher C,Nagy E,Meinke A,Mandl CW

    更新日期：2010-08-16 00:00:00

  • Construction and evaluation of an expression vector allowing the stable expression of foreign antigens in a Salmonella typhimurium vaccine strain.

    abstract：:Salmonella strains have great potential as live carriers of heterologous antigens to induce immunity against a variety of infectious diseases. However, the amount of heterologous antigen required to induce an adequate immune response may be toxic for the bacterium and result in cell death, overattenuation or loss of e...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(94)90336-0

    authors： Tijhaar EJ,Zheng-Xin Y,Karlas JA,Meyer TF,Stukart MJ,Osterhaus AD,Mooi FR

    更新日期：1994-08-01 00:00:00

  • Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations.

    abstract：:In response to global interest in the development of a universal influenza vaccine, the Bill & Melinda Gates Foundation, PATH, and the Global Funders Consortium for Universal Influenza Vaccine Development convened a meeting of experts (London, UK, May 2018) to assess the role of a standardized controlled human influen...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.06.053

    authors： Innis BL,Scorza FB,Blum JS,Jain VK,Aguilar AO,Post DJ,Roberts PC,Wairagkar N,White J,Bresee J

    更新日期：2019-08-14 00:00:00

  • Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada.

    abstract：BACKGROUND:The 10-valent protein D pneumococcal conjugate vaccine (PHiD-CV) was licensed on the basis of immunogenicity studies and there are no published data on its effectiveness to prevent invasive pneumococcal disease (IPD). In the province of Quebec, Canada, PHiD-CV was introduced in the summer of 2009, replacing ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.08.017

    authors： De Wals P,Lefebvre B,Defay F,Deceuninck G,Boulianne N

    更新日期：2012-10-05 00:00:00

  • Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial.

    abstract：BACKGROUND:We evaluated the safety and immunogenicity of liquid and lyophilized formulations of an investigational trivalent group B streptococcus (GBS) vaccine in non-pregnant women and assessed the formulations' equivalence in terms of serotype-specific immune response. METHODS:This phase II, randomized, comparative...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.02.085

    authors： Beran J,Leroux-Roels G,Van Damme P,de Hoon J,Vandermeulen C,Al-Ibrahim M,Johnson C,Peterson J,Baker S,Seidl C,Dreisbach A,Karsten A,Corsaro B,Henry O,Lattanzi M,Bebia Z

    更新日期：2020-04-03 00:00:00

  • Considerations regarding efficacy endpoints in HIV vaccine trials: executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise.

    abstract：:HIV vaccines of the first generation are, in contrast to most currently licensed vaccines, unlikely to provide sterilizing immunity against infection with HIV. However, they are expected to exert a beneficial effect on the maintenance of CD4 T-cell counts by reducing viral load. There is a recognized need for clarifyi...

    journal_title：Vaccine

    pub_type：

    doi：10.1016/j.vaccine.2008.12.029

    authors： Fruth U

    更新日期：2009-03-23 00:00:00

  • Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.

    abstract：:Respiratory syncytial virus (RSV) is the primary cause of serious lower respiratory tract illness in young children. We have engineered a recombinant candidate vaccine G1F/M2, consisting of a cytotoxic T lymphocyte (CTL) epitope of RSV-M2 protein and a domain of RSV-G protein. In this study, the long-term immunogenici...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.08.007

    authors： Zeng R,Qi X,Gong W,Mei X,Wei L,Ma C,Yin X

    更新日期：2007-10-16 00:00:00

  • Introduction to the supplement.

    abstract：:In July of 2014, a symposium entitled "Enhancing Vaccine Immunity and Value" was held in Siena, Italy. The focus of the symposium was on how to best meet the challenge of developing and implementing vaccines for future disease targets. Vaccination has been responsible for averting estimated 3 billion cases of disease ...

    journal_title：Vaccine

    pub_type： 社论

    doi：10.1016/j.vaccine.2015.02.072

    authors： Rappuoli R

    更新日期：2015-06-08 00:00:00

  • Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants.

    abstract：:Insoluble, pure protein particles could be advantageous as single-entity vaccines or as carriers for small peptide epitopes. Dense gas anti-solvent precipitation was employed to produce pure protein particles which were found to be insoluble in water. As particulate and multimerized antigens are more immunogenic and h...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.09.087

    authors： White PJ,Anastasopoulos F,Church JE,Kuo CY,Boyd BJ,Hickey PL,Tu LS,Burns P,Lew AM,Heath WR,Davey GM,Pouton CW

    更新日期：2008-12-09 00:00:00

  • Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits.

    abstract：:Millions of people worldwide are currently infected with human papillomaviruses (HPVs). A therapeutic HPV vaccine would have widespread applicability because HPV-associated lesions are difficult to treat and may progress to carcinoma. We developed three attenuated VSV recombinants expressing the cottontail rabbit papi...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.08.012

    authors： Brandsma JL,Shlyankevich M,Buonocore L,Roberts A,Becker SM,Rose JK

    更新日期：2007-01-08 00:00:00

  • Monitoring of rotavirus vaccination in Morocco: establishing the baseline burden of rotavirus disease.

    abstract：BACKGROUND:Rotavirus is a leading cause of childhood morbidity and mortality worldwide. Clinical trials for two rotavirus vaccines recommended by the WHO for global use since 2009 have successfully demonstrated the safety and efficacy of these vaccines in a wide range of countries. To control the burden of severe and f...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.08.058

    authors： Benhafid M,Rguig A,Trivedi T,Elqazoui M,Teleb N,Mouane N,Maltouf AF,Parashar U,Patel M,Aouad RE

    更新日期：2012-10-12 00:00:00

  • Sudden infant death syndrome (SIDS): are common bacterial toxins responsible, and do they have a vaccine potential?

    abstract：:Despite extensive research, no unifying concept has satisfactorily explained the cause of the sudden infant death syndrome (SIDS). The details are briefly outlined of some of the evidence supporting the hypothesis that common bacterial toxins are important in the aetiology of SIDS. These bacterial toxins act as trigge...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/0264-410x(94)90102-3

    authors： Murrell TG,Murrell WG,Lindsay JA

    更新日期：1994-03-01 00:00:00

  • Cost of plasma-derived hepatitis B vaccine production.

    abstract：:It is generally accepted that the introduction of hepatitis B vaccine to national programmes of immunization in developing countries is desirable, but it has so far been constrained by the high cost of the vaccine. To determine the potential minimal costs of the vaccine, a study has been carried out of the production ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(90)90101-q

    authors： Mahoney RT

    更新日期：1990-08-01 00:00:00

  • Economic evaluation of vaccination against influenza in the elderly: an experience from a population-based influenza vaccination program in Taiwan.

    abstract：:Due to viral strains, influenza season, and consultations and admission rates varying from country to country, the continued economic evaluation of influenza vaccination for the elderly people aged 65 years and above is paramount, particularly in areas with dense population. Efficacy and cost-effective analysis of inf...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.10.011

    authors： Wang ST,Lee LT,Chen LS,Chen TH

    更新日期：2005-03-14 00:00:00

  • Improving immunization data quality in Peru and Mexico: Two case studies highlighting challenges and lessons learned.

    abstract：INTRODUCTION:The Global Vaccine Action Plan and the Regional Immunization Action Plan of the Americas call for countries to improve immunization data quality. Immunization information systems, particularly electronic immunization registries (EIRs), can help to facilitate program management and increase coverage. Howeve...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.10.083

    authors： Trumbo SP,Contreras M,García AGF,Díaz FAE,Gómez M,Carrión V,Ruiz KJP,Aquije R,Danovaro-Holliday MC,Velandia-González M

    更新日期：2018-11-29 00:00:00

  • Use of GFP-expressing influenza viruses for the detection of influenza virus A/H5N1 neutralizing antibodies.

    abstract：:The hemagglutination inhibition (HI) assay is used most commonly for the detection of antibodies to influenza viruses. However, for the detection of antibodies to avian influenza viruses of the H5N1 subtype either induced by infection or by vaccination, the HI assay is insensitive. Therefore, the virus neutralization ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.02.082

    authors： Rimmelzwaan GF,Verburgh RJ,Nieuwkoop NJ,Bestebroer TM,Fouchier RA,Osterhaus AD

    更新日期：2011-04-18 00:00:00

  • Efficient influenza B virus propagation due to deficient interferon-induced antiviral activity in MDCK cells.

    abstract：:Influenza B virus infections are mainly restricted to humans, which is partially caused by the inability of influenza B virus NS1 protein to counteract the innate immune response of other species. However, for cell culture-based influenza vaccine production non-human cells, such as Madin-Darby canine kidney (MDCK) cel...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.05.069

    authors： Frensing T,Seitz C,Heynisch B,Patzina C,Kochs G,Reichl U

    更新日期：2011-09-22 00:00:00

  • Outer membrane PhoE protein of Escherichia coli as a carrier for foreign antigenic determinants: immunogenicity of epitopes of foot-and-mouth disease virus.

    abstract：:Outer membrane protein PhoE of Escherichia coli was used for the expression of antigenic determinants of foot-and-mouth disease virus. Five hybrid PhoE proteins were constructed containing different combinations of two antigenic determinants of VP1 protein of the virus. The hybrid proteins were expressed in two E. col...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(90)90184-n

    authors： Agterberg M,Adriaanse H,Lankhof H,Meloen R,Tommassen J

    更新日期：1990-02-01 00:00:00

  • Protection against filarial infection by 45-49 kDa molecules of Brugia malayi via IFN-γ-mediated iNOS induction.

    abstract：:Nitric oxide (NO) mediated mechanisms have been implicated in killing of some life-stages of Brugia malayi/Wuchereria bancrofti and protect the host through type 1 responses and IFN-γ stimulated toxic mediators' release. However, the identity of NO stimulating molecules of the parasites is not known. Three predominant...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.11.041

    authors： Verma SK,Joseph SK,Verma R,Kushwaha V,Parmar N,Yadav PK,Thota JR,Kar S,Murthy PK

    更新日期：2015-01-15 00:00:00